Literature DB >> 10231454

Bone histology in patients with nephrotic syndrome and normal renal function.

S K Mittal1, S C Dash, S C Tiwari, S K Agarwal, S Saxena, S Fishbane.   

Abstract

BACKGROUND: The prevalence of metabolic bone disease in patients with nephrotic syndrome (NS) at normal level of renal function remains uncertain.
METHODS: To address this issue, we studied 30 patients (20 men and 10 women, mean age 27.3 +/- 11.7 years) with NS who had normal renal function (mean creatinine clearance 103 +/- 4 ml/min). We evaluated their serum calcium, phosphorus, alkaline phosphatase, immunoreactive parathyroid hormone (iPTH), vitamin D metabolites, urinary calcium, and skeletal survey. The extent of bone mineralization was analyzed by histomorphometric analysis of iliac crest bone biopsy specimens in all patients. The findings on bone histology were correlated with biochemical parameters.
RESULTS: The mean duration of NS was 35.5 +/- 26.9 months, with a protein excretion of 7.3 +/- 3.2 g/24 hr and a serum albumin of 2.2 +/- 0.8 g/dl. Total serum calcium was 7.8 +/- 0.8 mg/dl, whereas ionized calcium was 5.7 +/- 0.7 mg/dl, phosphorus 3.2 +/- 1.2 mg/dl, and alkaline phosphatase 149 +/- 48.6 U/liter. Serum iPTH levels were normal in all except two patients. The mean serum 25-hydroxyvitamin D [25(OH)D] level was 3.9 +/- 1.2 ng/ml (normal 15 to 30 ng/ml), whereas 1,25-dihydroxyvitamin D was 24 +/- 4.7 pg/ml (normal 16 to 65). There was an inverse correlation between serum levels of 25(OH)D and the magnitude of proteinuria (r = -0.42, P < 0.05). The mean 24-hour urinary calcium excretion was 82 +/- 21 mg/day. The skeletal survey was normal in all patients. Bone histology was normal in 33.3% of the patients, whereas 56.7% had isolated osteomalacia (OSM), and 10% had an increased bone resorption in association with defective mineralization. The severity of OSM measured by mineralization lag time correlated linearly with the duration (r = 0.94, P < 0.0001) and the amount (r = 0.97, P < 0.0001) of proteinuria. All patients with NS for more than three years had histological changes. Patients with OSM had lower 25(OH)D and serum albumin as compared with those with normal histology (P < 0.005). Bone mineralization had no significant correlation with serum iPTH, divalent ions, or vitamin D levels.
CONCLUSIONS: OSM is a frequent finding in adult patients with NS, even at a normal level of renal function. Its severity correlates with the amount and duration of proteinuria.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10231454     DOI: 10.1046/j.1523-1755.1999.00413.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  12 in total

1.  Bone disease in nephrotic syndrome--prevention is better than cure.

Authors:  Sanjeev Gulati; Kiran Gulati
Journal:  Pediatr Nephrol       Date:  2005-01       Impact factor: 3.714

2.  Inducible podocyte-specific deletion of CTCF drives progressive kidney disease and bone abnormalities.

Authors:  Marta Christov; Abbe R Clark; Braden Corbin; Samy Hakroush; Eugene P Rhee; Hiroaki Saito; Dan Brooks; Eric Hesse; Mary Bouxsein; Niels Galjart; Ji Yong Jung; Peter Mundel; Harald Jüppner; Astrid Weins; Anna Greka
Journal:  JCI Insight       Date:  2018-02-22

Review 3.  Vitamin D deficiency and toxicity in chronic kidney disease: in search of the therapeutic window.

Authors:  Uwe Querfeld; Robert H Mak
Journal:  Pediatr Nephrol       Date:  2010-06-22       Impact factor: 3.714

Review 4.  Bone Health in Glomerular Kidney Disease.

Authors:  Dorey A Glenn; Michelle R Denburg
Journal:  Curr Osteoporos Rep       Date:  2019-12       Impact factor: 5.096

5.  Vitamin D and Albuminuria in Youth with and without Type 1 Diabetes.

Authors:  Debika Nandi-Munshi; Maryam Afkarian; Kathryn B Whitlock; Jamie L Crandell; Ronny A Bell; Ralph D'Agostino; Sharon Saydah; Amy K Mottl; Dana Dabelea; Mary Helen Black; Elizabeth J Mayer-Davis; Catherine Pihoker
Journal:  Horm Res Paediatr       Date:  2017-05-29       Impact factor: 2.852

6.  Vitamin D insufficiency in steroid-sensitive nephrotic syndrome in remission.

Authors:  Francis L Weng; Justine Shults; Rita M Herskovitz; Babette S Zemel; Mary B Leonard
Journal:  Pediatr Nephrol       Date:  2004-11-25       Impact factor: 3.714

7.  Prophylactic calcium and vitamin D treatments in steroid-treated children with nephrotic syndrome.

Authors:  Mustafa Bak; Erkin Serdaroglu; Rengin Guclu
Journal:  Pediatr Nephrol       Date:  2005-12-29       Impact factor: 3.714

8.  Bone histology in steroid-treated children with non-azotemic nephrotic syndrome.

Authors:  Michael Freundlich; Michael Jofe; William G Goodman; Isidro B Salusky
Journal:  Pediatr Nephrol       Date:  2004-02-26       Impact factor: 3.714

9.  Calcium, Vitamin D, and Bone Derangement in Nephrotic Syndrome.

Authors:  Samantha Peiling Yang; Lizhen Ong; Tze Ping Loh; Horng Ruey Chua; Cassandra Tham; Khoo Chin Meng; Lim Pin
Journal:  J ASEAN Fed Endocr Soc       Date:  2021-05-03

10.  Differences between hospitals in attainment of parathyroid hormone treatment targets in chronic kidney disease do not reflect differences in quality of care.

Authors:  Mieke J Peeters; Arjan D van Zuilen; Jan A J G van den Brand; Peter J Blankestijn; Marc A G J ten Dam; Jack F M Wetzels
Journal:  BMC Nephrol       Date:  2012-08-06       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.